FinTrust Capital Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

FinTrust Capital Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-74	Closed	–	–	1337
2022 Q1	$0	Hold	74	–	–	﹤0.01%	1315
2021 Q4	$0	Buy	+74	New	+$351	﹤0.01%	1273

Other funds holding PRTK

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

FinTrust Capital Advisors's PRTK Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 74 shares.

FinTrust Capital Advisors first reported a position in PRTK in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

FinTrust Capital Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
FinTrust Capital Advisors sold 74 Paratek Pharmaceuticals, Inc. shares in Q2 2022.
FinTrust Capital Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2021 and held it in 2 quarters.
FinTrust Capital Advisors's Paratek Pharmaceuticals, Inc. position peaked at $0 in Q1 2022.
84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.